Drugs / ENAVATUZUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00738764 | Jul 2008 → Oct 2011 | cancer | Abbott | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENAVATUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743011 ↗ |
| Known as | PDL192 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00738764 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 12A agonist” CHEMBL1743011 ↗ |
| Modality | Monoclonal antibody | “Humanized anti-TWEAK receptor monoclonal IgG1 antibody” NCT00738764 ↗ |
| Target | TNFRSF12A | “Tumor necrosis factor receptor superfamily member 12A agonist” CHEMBL1743011 ↗ |